PubMed Health⌕ Search

Biomedical subjects

B Norlander

Publications and source records attributed to B Norlander.

50 records · Page 3Linked to original sources

The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.

1 The absorption of a single oral dose of cimetidine taken on a fasting stomach or together with a meal was studied in 28 patients before and during 12 weeks treatment with cimetidine. 2 No significant changes in bioavailability were seen during treatment measured as the area under the blood concentration curve (AUC). 3 AUC after a single dose of 400 mg cimetidine was 2.05 times the area after a 200 mg dose. 4 There was a good correlation between AUC and the dose of cimetidine given corrected for body weight (r=0.89). 5 There was no difference in bioavailability if 200 mg cimetidine was taken on a fasting stomach or together with a beef steak meal. 6. During fasting conditions there was a peak in blood concentration at about one hour followed by a second unexplained peak during the third to fifth hour after dose administration. 7 With food the initial rise in blood concentrations was slower and there was only one peak occurring about 2 h after dose administration.

Adult↗

The influence of trichloroethylene and related drugs on the vestibular system.

A previously described experimental model for studying the effect of industrial solvents on the vestibular system of rabbits has been applied to trichloroethylene. Estimation of trichloroethylene and its metabolites in blood and cerebrospinal fluid was performed by gas chromatography. Vestibular function was studied by recording nystagmus, induced by positional changes or accelerated rotation. At blood levels of trichloroethylene above 30 p.p.m. "positional nystagmus" develops. Two metabolites of trichloroethylene, chloral hydrate and trichloroethanol, which are known as central nervous system (CNS) depressants, did not induce this abnormal nystagmus. However, alpha-chloralose, a derivative of chloral hydrate, induced positional nystagmus and also a markedly exaggerated nystagmus developed during rotatory acceleration. It is suggested that solvents like trichloroethylene elicit vestibular disturbances by stimulation of central subcortical vestibulo-oculomotor connections. The stimulation may be caused by a blockage of inhibitory systems.

Animals↗

Studies on hexachlorophene-induced myelin lesions in the trigeminal root transitional region in developing and adult mice.

Hexachlorophene (HCP)-induced intramyelinic vacuolation was studied in the transitional region of the trigeminal root of suckling and adult mice. HCP produced an extensive vacuolation in the central compartment of the region in both suckling and adult mice, while in the peripheral compartment myelin lesions were only seen in mice less than 16 days of age. Gas chromatographic measurements showed that in suckling mice the blood concentration of HCP decreased with age, apparently reflecting a faster elimination of HCP from the blood. By substantially increasing the HCP dose, higher blood concentrations were obtained in adult than less the 16-day-old mice; in spite of this, PNS myelin changes occurred only in the latter. Thus, by observing the HCP effect on the transitional region, where CNS and PNS directly meet, it is concluded that CNS of both suckling and adult mice is more severely effected by HCP than PNS, and that the reaction of the PNS myelin is age-dependent during the period of myelinogenesis; it is particularly vulnerable to a cytotoxic edema inducing substance.

Age Factors↗

Gaschromatography of clemastine. A study of plasma kinetics and biological effect.

A method for estimation of clemastine in human plasma has been developed. By chronic acid oxidation the drug is degradated to chlorobenzophenone, which can then be analysed by gas-liquid-chromatography using electron-capture detection. The plasma levels of clemastine after oral and i.v. administration have been studied. Using different methods for extraction of the drug from plasma a metabolic degradation of the pyrrolidine part of clemastine is demonstrated. The metabolite proposed may be biologically active. The plasma level of the drug was found to be directly related to its biologic effect, measured as inhibition of the histamine-induced flare in human skin.

Administration, Oral↗

Acetylation of procaine amide in man. A preliminary communication.

The metabolism of procaine amide was studied in 41 cardiac patients who had achieved steady state plasma concentrations of the drug. Acetylated procaine amide accounted for 31 +/- 12% (range 16-63%) of the overall urinary recovery of the drug and is therefore a main metabolite in man. Plasma levels of the metabolite were usually lower but sometimes exceeded those of the parent compound with variations between 1 and 15 mug/ml. The metabolite had a weaker effect than procaine amide on the maximal electrical driving velocity of isolated atrial strips from guinea pig.

Acetylation↗

Pharmacokinetics of cimetidine after single doses and during continuous treatment.

The plasma concentration-time curve and urinary excretion of cimetidine were followed in 10 patients after single 200mg doses given intravenously, in 9 patients after 400 and 800mg single oral doses, and in 10 patients over a 24-hour period during continuous oral treatment with 1000mg daily. The bioavailability of cimetidine measured as the ratio between the areas under the plasma concentration-time curves (AUC) after oral and intravenous administration was 76%. The mean excretion of cimetidine in the urine as unchanged drug, expressed as a percentage of administered dose, was 58% after 200mg intravenously and between 37 and 41% after single oral doses of 200, 400 and 800mg and during continuous treatment with 1.0g/day. Since there were no significant differences between the oral doses, the relative bioavailability of cimetidine does not appear to be dose-dependent. The AUC after the 800mg dose was 2.1 times that of the 400mg dose. No dose-dependent kinetics were observed. There were also no significant differences in the AUCs after 200 and 400mg doses during continuous treatment compared with the AUCs after the same single doses. Thus, cimetidine does not appear to induce or inhibit its own metabolism during treatment. Following intravenous administration, the mean volume of distribution was 1.39L/kg and the mean total body clearance and the mean plasma renal clearance of cimetidine were 655 and 375ml/min, respectively. A renal clearance of cimetidine more than 3 times higher than the creatinine clearance demonstrates that the renal excretion of cimetidine is mainly by tubular secretion. Plasma concentrations of cimetidine during continuous treatment with 1.0g/day were above 1.0 microgram/ml-the plasma concentration associated with 50% inhibition of stimulated acid secretion in peptic ulcer patients-for 9 out of the 24 hours. A morning plasma concentration above 0.6 microgram/ml before the next morning dose has been taken during treatment with cimetidine 1.0g/day is only seen in patients with some degree of renal failure. Measurement of plasma half-life during continuous treatment shows that the plasma half-life is longer than the mean 1.79 hours estimated after intravenous administration of a single dose.

Adult↗

Steady-state kinetics and dosage requirements of cimetidine in renal failure.

25 patients with different degrees of chronic stable renal failure received oral treatment with cimetidine over 6 days and a final dose in the morning of day 7. The doses of cimetidine were reduced according to the degree of renal failure. Plasma concentrations of cimetidine were determined before the morning dose on days 2,3,6 and before the final morning dose and during the day on day 7. 24-hour excretions of cimetidine were measured during the study and on day 7, 6 to 9 hours after the final morning dose. There were significant linear relationships between the values of creatinine clearance and plasma elimination rate constant of cimetidine (p less than 0.0025) and between the values of creatinine clearance and renal clearance of cimetidine (p less than 0.05). On the basis of the morning plasma concentrations before and the plasma concentration curve after the final morning dose on day 7 the following dose recommendations according to pretrial values of creatinine clearance are recommended for cimetidine treatment in renal failure: 5 to 15ml/min 200mg 2 or 3 times daily, 15 to 30ml/min 200mg 3 times daily and 30 to 75ml/min 200mg 4 times daily.

Adult↗

Tissue disposition of glyceryl trinitrate, 1,2-glyceryl dinitrate, and 1,3-glyceryl dinitrate in tolerant and nontolerant rats.

The tissue distribution of glyceryl trinitrate (GTN) and its two dinitrate metabolites 1,2-glyceryl dinitrate (1,2-GDN) and 1,3-glyceryl trinitrate (1,3-GDN), was studied in GTN-tolerant and nontolerant male Sprague-Dawley rats. The concentrations of GTN, 1,2-GDN, and 1,3-GDN were measured in plasma, heart, brain, liver, aortic tissue, and adipose tissue at various time points after a subcutaneous dose of GTN (50 mg/kg). At the first time point (5 hr), concentrations of GTN, 1,2-GDN, and 1,3-GDN in plasma were equal for tolerant and nontolerant rats, but the elimination rate was altered for the tolerant rats as compared with nontolerant rats. In adipose tissue, the concentration of GTN was significantly higher as compared with concentrations of the dinitrate metabolites. In contrast, the other tissues studied showed significantly higher concentrations of the GDNs when compared with GTN. The 1,3-GDN/1,2-GDN ratio decreased with time for both tolerant and nontolerant rats. This study indicates that long-term GTN administration results not only in tolerance development, but also in altered pharmacokinetics of GTN, 1,2-GDN, and 1,3-GDN. The results also show that the 1,3-GDN/1,2-GDN ratio is dependent on the GTN concentration.

Animals↗